Status:

COMPLETED

Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII)

Lead Sponsor:

Boston University

Collaborating Sponsors:

University of Witwatersrand, South Africa

Bill and Melinda Gates Foundation

Conditions:

HIV/AIDS

Antiretroviral Therapy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients ...

Detailed Description

SLATE II is be a pragmatic, individually randomized evaluation to determine the effectiveness of the revised algorithm in increasing ART initiation, compared to standard care, among non-pregnant adult...

Eligibility Criteria

Inclusion

  • Adult patients (\>18 years) (initiating children and adolescents on ART is likely to require additional information and adherence support, making the SLATE algorithm less applicable to pediatric populations)
  • Confirmed HIV-positive test result at any time (may have been diagnosed previously)
  • Self-report that patient is not currently on ART and has not been prescribed ART in the past three months
  • Presented at the study clinic for any HIV-related reason or other reason that led to referral for HIV testing or care

Exclusion

  • Pregnant (pregnancy is an exclusion criterion because treatment guidelines for pregnant women differ from those for non-pregnant adults; most pregnant women are diagnosed with HIV and initiated on ART in antenatal clinics, not general adult HIV clinics)
  • Not intending to return to this clinic for further HIV care in the coming year (i.e. intends to seek further care somewhere else)
  • Not willing to be traced by phone or in person for follow-up care if test results received after the enrollment visit indicate that further care is needed
  • Not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff
  • Not willing or able to provide written informed consent to participate in the study
  • Previously enrolled in the same study or the SLATE I study

Key Trial Info

Start Date :

March 14 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2020

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT03315013

Start Date

March 14 2018

End Date

December 31 2020

Last Update

January 22 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Health Economics and Epidemiology Research Office

Johannesburg, Gauteng, South Africa